Rezonic FDA Approval Status
Rezonic (casopitant) is an investigational NK-1 receptor antagonist in development as add-on therapy for the prevention of chemotherapy-induced nausea and vomiting, and also for the prevention of postoperative nausea and vomiting.
Development Timeline for Rezonic
|Sep 28, 2009||GSK Provides Update on Regulatory Filings for Zunrisa/Rezonic|
|May 29, 2008||GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic/Zunrisa (Casopitant)|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.